Skip to main content

Siliq (Brodalumab) & Hospitalized Neutropenia, Myocardial Infarction and Stroke, and Serious Infection

Basic Details
Status
Ongoing
Last Updated
Tuesday, November 19, 2024
Original Posting Date
Health Outcome(s)
hospitalized neutropenia
myocardial infarction and stroke
serious infection
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Result(s) (3)
Utilization of Brodalumab: A Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis
Regulatory Link(s) (1)
FDA Approval Package Materials